Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

More documents

Recommendations

Info

APPENDIX 9. Healthcare Research Centres (cont’d) RESEARCH CENTRE/ URL CONTACT DESCRIPTION 264 FIP BCCA oversees clinical and research activities related to PET/CT imaging at the BCCA. FIP BCCA operates the only clinical PET/CT scanner in B.C., located at the Vancouver Centre. FIP BCCA also has a state-of-the art small animal PET/CT scanner housed at the B.C. Cancer Research Centre which is used for pre-clinical studies. Construction of a new 6000 sq ft cyclotron and radiopharmaceutical production and research facility is underway and this will provide space for a 2nd PET/CT scanner. It will enable sustainable FDG production as a diagnostic radiopharmaceutical, providing opportunities for new radiotracer development and clinical trials. FIP BCCA Centre of Excellence for Functional Cancer Imaging is being developed to: • Improve cancer diagnosis and treatment planning for patients and health care professionals • Build research programs for the discovery, development and application of new radiotracers • Apply new advances in imaging to improve prevention, early diagnosis and management of cancers B.C. Cancer Agency - Vancouver Centre 600 West 10th Avenue Vancouver B.C. V5Z 4E6 Medical Director: Don Wilson dowilson@bccancer.bc.ca Tel: 604-707-5979 Contact: Francois Benard, Scientific Director fbenard@bccrc.ca Functional Imaging Program (FIP) BCCA www.bccrc.ca/ci/ www.bccrc.ca/at/athomefunctionalimaging.html • Collaborate in a growing national and international network of functional imaging programs. Tel: 604-675-8206 The VPC research and clinical team focuses its efforts on fighting prostate cancer through improved understanding of prevention, diagnosis, and treatment, as well as patient education. PC–TRIADD is a translational research centre and designated Centre of Excellence for Commercialization and Research focused on improving outcomes in prostate cancer. The VPC houses a large biorepository of untreated and post-treated prostate, bladder, and kidney cancers for target and biomarker characterization studies. It prides itself on its ability to move laboratory discoveries through the checks and balances of clinical trials and eventually to develop these research findings into new and more effective treatments. VPC/PC-TRIADD research interests include: • Pre-clinical and clinical evaluation of novel anti-cancer inhibitors • Elucidation of mechanisms of androgen-independent progression • Gene targeting device • Role of androgens in promoting prostate tumor Diamond Health Care Centre 6th Floor 2775 Laurel Street Vancouver, B.C. V5Z 1M9 VPC Prostate Research Facility 2660 Oak Street Vancouver, B.C., V6H 3Z6 Tel: 604-875-4818 Fax: 604-875-5654 info@prostatecentre.com The Vancouver Prostate Centre, including the: Translational Research Initiative for Accelerated Discovery and Development (PC- TRIADD) VCHRI www.prostatecentre. com • Psycho-social aspects of prostate disease. www.pctriadd.com Finlandia has recently partnered with InspireHealth, Canada’s only government funded, research-based integrated cancer care centre. Its program strongly promotes personal engagement in health through nutrition, exercise, and emotional and spiritual support— vital components for optimal cancer care, health and healing. 1111 West Broadway, Vancouver, B.C. V6H 1G1 Tel: 604-733-5323 Toll free: 1-800-363-4372 Finlandia Natural Pharmacy www.finlandiahealth. com BRITISH COLUMBIA Fax: 604-733-5340 InspireHealth is located in Vancouver, and is Canada’s foremost integrated cancer care centre, leading the way through research and innovative cancer care programs integrated with conventional cancer treatment. InspireHealth medical doctors have helped guide more than 5,500 patients to integrate research-informed natural approaches to health into their cancer treatment and recovery. There is growing evidence that these natural approaches to supporting health and immune system function can significantly decrease the risk of cancer recurrence and increase survival. #200—1330 West 8th Avenue Vancouver, B.C. V6H 4A6 Tel: 604-734-7125 Fax: 604-734-7105 info@inspirehealth.ca Chief Executive Officer Hal Gunn Contact: Stephanie Klaus, Development Manager InspireHealth www.inspirehealth. ca/
CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP RESEARCH CENTRE/ URL CONTACT DESCRIPTION 4. INFECTIOUS DISEASE SPECIFIC RESEARCH INSTITUTES B.C. Centre for Disease 655 West 12th Avenue BCCDC provides provincial and national leadership in public health through surveillance, detection, treatment, prevention and consulta- Control Vancouver, B.C. V5Z 4R4 tion services. BCCDC provides both direct diagnostic and treatment services for people with diseases of public health importance and www.bccdc.ca Tel: 604-707-2400 analytical and policy support to all levels of government and health authorities. Fax: 604-707-2401 BCCDC investigates and evaluates the occurrence of communicable diseases in B.C. and is the provincial reporting centre for reportable admininfo@bccdc.ca cases and categories of communicable diseases. In addition, the Centre creates opportunities for scientists, health professionals, university and other partners to contribute their knowledge and experience in resolving the outstanding health challenges facing British Columbians. BCCDC is an agency of the Provincial Health Services Authority. Scientific and technical support is provided by the following specialized divisions. These divisions supply statistics and reports in disease surveillance, and research publications in disease outcomes and treatment: • Epidemiology Services • Vaccine and Pharmacy Services • Hepatitis Division • STI/HIV Prevention and Control • Tuberculosis Control • Mathematical Modelling Unit • Public Health Emergency Management • Environmental Health Services • UBC Centre for Disease Control. B.C. Centre for Excel- St. Paul’s Hospital Providence Centre for Excellence HIV clinical research program focuses on further defining the role of antiretroviral therapy for the treatment of HIV lence in HIV/AIDS Healthcare infection. www.cfenet.ubc.ca 608 - 1081 Burrard Street CFE HIV Current priorities include: Vancouver B.C. V6Z 1Y6 • The evaluation of antiretroviral safety and efficacy of specific treatment regimens, simplified regimens, adjunctive therapies and new Director: Dr. Julio Montaner formulations of existing drugs. Tel: 604-806-8477 • Investigations into treatments for HIV patients co-infected with other viruses, such as hepatitis B and C. Fax: 604-806-9044 • New approaches to the treatment of HIV-related opportunistic infections; and investigations related to drug toxicities and metabolic risk Contact: Marianne Harris factors associated with HIV. Tel: 604-806-8771 The clinical team includes individuals with expertise in all areas of HIV care with special emphasis on primary care, infectious diseases, mharris@cfenet.ubc.ca respiratory medicine, lipid disorders, counselling and psychology, and clinical trial operations. CIHR Canadian HIV 620B - 1081 Burrard Street CTN is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV/AIDS, pharmaceutical manufacturers Trials Network Vancouver, B.C. V6Z 1Y6 and others that facilitates HIV/AIDS clinical trials of the highest scientific and ethical standards. www.hivnet.ubc.ca Tel: 604-806-8327 CTN provides a national and regional infrastructure to facilitate clinical trials in HIV/AIDS. CTN Core Research teams develop a clinical trial, Fax: 604-806-8210 from first concept to final protocol. CTN managers, statisticians, data methodologists, communications officers and others also assist in Toll Free: 1-800-661-4664 managing all aspects of an HIV trial. Director: Martin Schecter CTN Core research Teams focus on four areas of HIV research: Contact: Aslam Anis, National Co- • Antiretroviral Therapies Director • Clinical Management Science Tel: 604-806-8712 • Concurrent Diseases and Vulnerable Populations aslam.anis@ubc.ca • Vaccines and Immunotherapies. 265
Page 1:
1 33 0 34 0 M A G N E T I C V A R 9
Page 4 and 5:
ii BRITISH COLUMBIA
Page 6 and 7:
2 EXECUTIVE SUMMARY BRITISH COLUMBI
Page 8 and 9:
4 INTRODUCTION BRITISH COLUMBIA Wit
Page 10 and 11:
6 Health Authority (URL) Key Facili
Page 12 and 13:
8 FIGURE 2. Clinical Trials Units,
Page 14 and 15:
10 Facility (URL if available) Pedi
Page 16 and 17:
12 Facility (URL if available) Mood
Page 18 and 19:
14 Facility (URL if available) Down
Page 20 and 21:
16 Facility (URL if available) Clin
Page 22 and 23:
18 Facility (URL if available) Gast
Page 24 and 25:
20 TABLE 3. Clinical Trials Support
Page 26 and 27:
22 Much clinical research - particu
Page 28 and 29:
24 FIGURE 3. Source of Funds for Cl
Page 30 and 31:
26 BRITISH COLUMBIA FIGURE 7. Thera
Page 32 and 33:
28 BRITISH COLUMBIA Clinical Invest
Page 34 and 35:
Disease Area Population Information
Page 36 and 37:
32 CV/Cardiology CNS Pulmonary Canc
Page 38 and 39:
34 TABLE 9. Health Economics and He
Page 40 and 41:
36 TABLE 10. Epidemiology and Surve
Page 42 and 43:
38 TABLE 12. Provincial Networks Th
Page 44 and 45:
40 Network B.C. Investigator’s Ro
Page 46 and 47:
42 Network B.C. Investigator’s Ro
Page 48 and 49:
44 TABLE 14. Independent Clinical T
Page 50 and 51:
46 COMPARATIVE POSITIONING OF B.C.
Page 52 and 53:
48 ACKNOWLEDGEMENTS BRITISH COLUMBI
Page 54 and 55:
50 APPENDIX 1-2 TABLE OF CONTENTS B
Page 56 and 57:
52 PROVINCIAL HEALTH SERVICES AUTHO
Page 58 and 59:
54 BRITISH COLUMBIA Edward Miller C
Page 60 and 61:
56 BRITISH COLUMBIA Radiation Thera
Page 62 and 63:
58 The Unit has 15 Principal Invest
Page 64 and 65:
60 BRITISH COLUMBIA Neonatal Resear
Page 66 and 67:
62 The B.C. Children’s Hospital p
Page 68 and 69:
64 BRITISH COLUMBIA The clinical tr
Page 70 and 71:
66 FRASER HEALTH AUTHORITY BRITISH
Page 72 and 73:
68 BRITISH COLUMBIA tional therapis
Page 74 and 75:
70 PROVIDENCE HEALTH CARE SOCIETY 4
Page 76 and 77:
72 BRITISH COLUMBIA Quality control
Page 78 and 79:
74 Clinical trials investigators in
Page 80 and 81:
76 The facility has 13 investigator
Page 82 and 83:
78 Staffing of the Centre is as fol
Page 84 and 85:
80 Investigators: • Ayas, Najib
Page 86 and 87:
82 BRITISH COLUMBIA Quality control
Page 88 and 89:
84 The Research Group consists of t
Page 90 and 91:
86 BRITISH COLUMBIA Multiple Sclero
Page 92 and 93:
88 BRITISH COLUMBIA Gastroenterolog
Page 94 and 95:
Since the Centre is located in St.
Page 96 and 97:
TABLE A1. Providence Health Care So
Page 98 and 99:
94 BRITISH COLUMBIA FIGURE A9. Cent
Page 100 and 101:
96 BRITISH COLUMBIA The Unit suppor
Page 102 and 103:
TABLE A2. CFRI Program-affiliated R
Page 104 and 105:
100 BRITISH COLUMBIA Quality contro
Page 106 and 107:
102 BRITISH COLUMBIA • Knowledge
Page 108 and 109:
104 Its staffing is as follows: Stu
Page 110 and 111:
106 APPENDIX 3. QUALITY CONTROL/ QU
Page 112 and 113:
APPENDIX 5. CLINICAL TRIALS TRAININ
Page 114 and 115:
APPENDIX 5. Clinical Trials Trainin
Page 116 and 117:
112 APPENDIX 6 TABLE OF CONTENTS BR
Page 118 and 119:
6.1 Clinical Trials Researchers Lis
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219: 6.2 Clinical Trials Researchers Lis
Page 242 and 243: Pediatrics INSTITUTION EMAIL URL DI
Page 244 and 245: Pediatrics (cont’d) INSTITUTION E
Page 252 and 253: 248 APPENDICES 7-13 TABLE OF CONTEN
Page 254 and 255: 250 TABLE A3. Patient and Addiction
Page 256 and 257: 252 TABLE A3. Patient and Addiction
Page 258 and 259: APPENDIX 8. PROVINCIAL AND NATIONAL
Page 260 and 261: APPENDIX 8. Provincial And National
Page 262 and 263: 258 APPENDIX 9. Healthcare Research
Page 264 and 265: APPENDIX 9. Healthcare Research Cen
Page 288 and 289: APPENDIX 10. NATIONAL AND INTERNATI
Page 290 and 291: Networks In Which B.C.’s Clinical
Page 296 and 297: APPENDIX 11. INDEPENDENT CLINICAL T
Page 298 and 299: APPENDIX 11. Independent Clinical T
Page 310 and 311: APPENDIX 12. PRECLINICAL STUDIES SE
Page 312 and 313: APPENDIX 12. Preclinical Studies Se
Page 314 and 315: APPENDIX 12. Preclinical Studies Se
Page 316 and 317: 312 B.C. Centre for Disease Control
Page 318 and 319:
314 University of Victoria Brenda D
Page 320:
316 BRITISH COLUMBIA
show all

Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?